Stock AnalizImmunocore Holdings plc IMCR
Biotechnology: Biological Products (No Diagnostic Substances) · IPO 2021 · data as of November 13, 2026
Immunocore Holdings plc (IMCR) is a healthcare company listed in the US with a market value of about $1.5B. In the twelve months to September 30, 2026 it had revenue of $429M and net income of -$32M, a net margin of -7.5%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (4/5); the weakest is value (0/5).
Key numbers: 5-year revenue growth of 58% a year, a 5-year average ROIC of -19%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 86% below the current price.
Score: 1.2 / 5
Checks passed
- Revenue growth above 10% last year
- 3-year revenue growth above 10% a year
- Profit margin improving
- Strong R&D investment or growth above 20%
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- Price below intrinsic value (DCF, moderate assumptions)
- PEG below 1.5
- 3-year free cash flow growth above 10% a year
- 5-year EPS growth above 10% a year
- 5-year average ROIC above 12%
Valuation
Growth and quality
Financials, last 8 years
| Fiscal year | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $429M | $400M | $310M | $249M | $174M | $36M | $41M | $34M | $30M |
| Net income | -$32M | -$36M | -$51M | -$55M | -$53M | -$180M | -$101M | -$137M | -$92M |
| Free cash flow | -$18M | -$15M | $21M | -$2M | -$51M | -$144M | -$88M | -$141M | -$26M |
| EPS (diluted) | $-0.63 | $-0.69 | $-0.99 | $-1.07 | $-1.02 | $-3.48 | $-1.96 | $-2.66 | $-1.77 |
| Net margin | -7.5% | -8.9% | -16.5% | -22.2% | -30.1% | -493.4% | -246.0% | -404.9% | -302.8% |
| ROIC | — | -8.4% | -16.9% | -13.4% | -9.7% | -48.6% | -78.6% | -287.2% | -134.2% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
What analysts expect
The average 12-month price target from 10 analysts is $59.40, 98% above the current price; targets range from $33.00 to $84.00; the consensus rating is “Buy”; expected EPS is $-0.24 for the fiscal year ending December 31, 2026.
Frequently asked questions
Is Immunocore Holdings stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 86% below the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Immunocore Holdings pay a dividend?
Not currently.
Is Immunocore Holdings a good stock to buy?
We do not give buy or sell advice. Immunocore Holdings scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.